nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.12.2020 | Review

Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis

verfasst von: A. Pizzocaro, W. Vena, R. Condorelli, A. Radicioni, G. Rastrelli, D. Pasquali, R. Selice, A. Ferlin, C. Foresta, E. A. Jannini, M. Maggi, A. Lenzi, R. Pivonello, A. M. Isidori, A. Garolla, S. Francavilla, G. Corona, the King, Klinefelter ItaliaN Group

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Low testosterone (T) in Klinefelter’s syndrome (KS) can contribute to typical features of the syndrome such as reduced bone mineral density, obesity, metabolic disturbances and increased cardiovascular risk. The aim of the present study is to review and meta-analyze all available information regarding possible differences in metabolic and bone homeostasis profile between T treated (TRT) or untreated KS and age-matched controls.

Methods

We conducted a random effect meta-analysis considering all the available data from observational or randomized controlled studies comparing TRT-treated and untreated KS and age-matched controls. Data were derived from an extensive MEDLINE, Embase, and Cochrane search.

Results

Out of 799 retrieved articles, 21 observational and 22 interventional studies were included in the study. Retrieved trials included 1144 KS subjects and 1284 healthy controls. Not-treated KS patients showed worse metabolic profiles (including higher fasting glycemia and HOMA index as well as reduced HDL-cholesterol and higher LDL-cholesterol) and body composition (higher body mass index and waist circumference) and reduced bone mineral density (BMD) when compared to age-matched controls. TRT in hypogonadal KS subjects was able to improve body composition and BMD at spinal levels but it was ineffective in ameliorating lipid and glycemic profile. Accordingly, TRT-treated KS subjects still present worse metabolic parameters when compared to age-matched controls.

Conclusion

TRT outcomes observed in KS regarding BMD, body composition and glyco-metabolic control, are similar to those observed in male with hypogonadism not related to KS. Moreover, body composition and BMD are better in treated than untreated hypogonadal KS. Larger and longer randomized placebo-controlled trials are advisable to better confirm the present data, mainly derived from observational studies.

Nur mit Berechtigung zugänglich

Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A, Klinefelter ItaliaN Group (KING) (2017) Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. J Endocrinol Investig 40:123–134. https://doi.org/10.1530/EJE-17-0902CrossRef

Gravholt CH, Chang S, Wallentin M, Fedder J, Moore P, Skakkebæk A (2018) Klinefelter syndrome: integrating genetics, neuropsychology, and endocrinology. Endocr Rev 39:389–423. https://doi.org/10.1210/er.2017-00212CrossRefPubMed

Aksglaede L, Skakkebaek NE, Almstrup K, Juul A (2011) Clinical and biological parameters in 166 boys, adolescents and adults with nonmosaic Klinefelter syndrome: a Copenhagen experience. Acta Paediatr 100:793–806. https://doi.org/10.1111/j.1651-2227.2011.02246.xCrossRefPubMed

Calogero AE, Giagulli VA, Mongioì LM, Triggiani V, Radicioni AF, Jannini EA, Pasquali D, Klinefelter ItaliaN Group (KING) (2017) Klinefelter syndrome: cardiovascular abnormalities and metabolic disorders. J Endocrinol Investig 40:705–712. https://doi.org/10.1007/s40618-017-0619-9CrossRef

Corona G, Vignozzi L, Sforza A, Maggi M (2013) Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 31:103–125. https://doi.org/10.5534/wjmh.2013.31.2.103CrossRefPubMedPubMedCentral

Haider A, Saad F, Doros G, Gooren L (2014) Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 8:e339–349. https://doi.org/10.1016/j.orcp.2013.10.005CrossRefPubMed

Yassin A, Haider A, Haider KS, Caliber M, Doros G, Saad F, Garvey WT (2019) Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care 42:1104–1111. https://doi.org/10.2337/dc18-2388CrossRefPubMed

Corona G, Maseroli E, Maggi M (2014) Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother 15:1903–1926. https://doi.org/10.1517/14656566.2014.944896CrossRefPubMed

Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M (2016) Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Investig 39:967–981. https://doi.org/10.1007/s40618-016-0480-2CrossRef

10.

Grossmann M, Ng Tang Fui M, Cheung AS (2019) Late-onset hypogonadism: metabolic impact. Andrology. https://doi.org/10.1111/andr.12705CrossRefPubMed

11.

Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, Saad F, Mannucci E, Maggi M (2016) Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 174:99–116. https://doi.org/10.1530/EJE-15-0262CrossRef

12.

Grossmann M (2018) Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol (Oxf) 89:11–21. https://doi.org/10.1111/cen.13723CrossRef

13.

Goodale T, Sadhu A, Petak S, Robbins R (2017) Testosterone and the heart. Methodist Debakey Cardiovasc J 13:68–72. https://doi.org/10.14797/mdcj-13-2-68

14.

Rastrelli G, Maggi M, Corona G (2018) Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol 11:439–458. https://doi.org/10.1080/17512433.2018.1445969CrossRefPubMed

15.

Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 6:272–285. https://doi.org/10.1111/andr.12470CrossRefPubMed

16.

Høst C, Bojesen A, Erlandsen M, Groth K, Kritstensen K, Jurik AG, Birkebæk N, Gravholt C (2019) A placebo-controlled randomized study with testosterone in Klinefelter syndrome—beneficial effects on body composition. Endocr Connect 8:1250–1261. https://doi.org/10.1530/EC-19-0323CrossRefPubMedPubMedCentral

17.

Watanabe H, Igari D, Tanahashi Y, Harada K, Saito M (1974) Measurements of size and weight of prostate by means of transrectal ultrasonotomography. Tohoku J Exp Med 114:277–285. https://doi.org/10.1620/tjem.114.277CrossRefPubMed

18.

Horowitz M, Wishart JM, O'Loughlin PD, Morris HA, Need AG, Nordin BE (1992) Osteoporosis and Klinefelter's syndrome. Clin Endocrinol (Oxf) 36:113–118. https://doi.org/10.1111/j.1365-2265.1992.tb02910.xCrossRef

19.

Kamischke A, Baumgardt A, Horst J, Nieschlag E (2003) Clinical and diagnostic features of patients with suspected Klinefelter syndrome. J Androl 24:41–48. https://doi.org/10.1002/j.1939-4640.2003.tb02638.xCrossRefPubMed

20.

Yesilova Z, Ozata M, Oktenli C, Sanisoglu SY, Erbil MK, Dagalp K (2004) Effect of supraphysiologic doses of testosterone on fasting plasma total homocysteine concentrations in men with Klinefelter's syndrome. Fertil Steril 81:1278–1282. https://doi.org/10.1016/j.fertnstert.2003.11.029CrossRefPubMed

21.

Yesilova Z, Oktenli C, Sanisoglu SY, Musabak U, Cakir E, Ozata M, Dagalp K (2005) Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study. Endocrine 27:11–15. https://doi.org/10.1385/ENDO:27:1:011CrossRefPubMed

22.

Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH (2006) The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 29:1591–1598. https://doi.org/10.2337/dc06-0145CrossRefPubMed

23.

Seo JT, Lee JS, Oh TH, Joo KJ (2007) The clinical significance of bone mineral density and testosterone levels in Korean men with non-mosaic Klinefelter's syndrome. BJU Int 99:141–146. https://doi.org/10.1111/j.1464-410X.2006.06584.xCrossRefPubMed

24.

Høst C, Bojesen A, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH (2010) Effect of sex hormone treatment on circulating adiponectin and subforms in Turner and Klinefelter syndrome. Eur J Clin Investig 40:211–219. https://doi.org/10.1111/j.1365-2362.2009.02250.xCrossRef

25.

Bojesen A, Høst C, Gravholt CH (2010) Klinefelter's syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. Mol Hum Reprod 16:396–401. https://doi.org/10.1093/molehr/gaq016CrossRefPubMed

26.

Ferlin A, Schipilliti M, Vinanzi C, Garolla A, Di Mambro A, Selice R, Lenzi A, Foresta C (2011) Bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism. J Clin Endocrinol Metab 96:E739–E745. https://doi.org/10.1210/jc.2010-1878CrossRefPubMed

27.

Hiéronimus S, Lussiez V, Le Duff F, Ferrari P, Bständig B, Fénichel P (2011) Klinefelter's syndrome and bone mineral density: is osteoporosis a constant feature? Ann Endocrinol (Paris) 72:14–18. https://doi.org/10.1016/j.ando.2010.10.002CrossRef

28.

Bak CW, Byun JS, Lee JH, Park JH, Lee KA, Shim SH (2012) Clinical and social characteristics of Korean men with Klinefelter syndrome. Int J Urol 19:443–449. https://doi.org/10.1111/j.1442-2042.2012.02964.xCrossRefPubMed

29.

Foresta C, Caretta N, Palego P, Ferlin A, Zuccarello D, Lenzi A, Selice R (2012) Reduced artery diameters in Klinefelter syndrome. Int J Androl 35:720–725. https://doi.org/10.1111/j.1365-2605.2012.01269.xCrossRefPubMed

30.

Pasquali D, Arcopinto M, Renzullo A, Rotondi M, Accardo G, Salzano A, Esposito D, Saldamarco L, Isidori AM, Marra AM, Ruvolo A, Napoli R, Bossone E, Lenzi A, Baliga RR, Saccà L, Cittadini A (2013) Cardiovascular abnormalities in Klinefelter syndrome. Int J Cardiol 168:754–759. https://doi.org/10.1016/j.ijcard.2012.09.215CrossRefPubMed

31.

Selice R, Caretta N, Di Mambro A, Torino M, Palego P, Ferlin A, Foresta C (2013) Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome. Eur J Endocrinol 169:743–749. https://doi.org/10.1530/EJE-13-0488CrossRefPubMed

32.

Shanbhogue VV, Hansen S, Jørgensen NR, Brixen K, Gravholt CH (2014) Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in Klinefelter syndrome. J Bone Miner Res 29:2474–2482. https://doi.org/10.1002/jbmr.2272CrossRefPubMed

33.

Chang S, Skakkebæk A, Gravholt CH (2015) Klinefelter Syndrome and medical treatment: hypogonadism and beyond. Hormones (Athens) 14:531–548. https://doi.org/10.14310/horm.2002.1622

34.

Ferlin A, Selice R, Di Mambro A, Ghezzi M, Di Nisio A, Caretta N, Foresta C (2015) Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome. Osteoporos Int 26:2193–2202. https://doi.org/10.1007/s00198-015-3136-8CrossRefPubMed

35.

Jørgensen IN, Skakkebaek A, Andersen NH, Pedersen LN, Hougaard DM, Bojesen A, Trolle C, Gravholt CH (2015) Short QTc interval in males with klinefelter syndrome-influence of CAG repeat length, body composition, and testosterone replacement therapy. Pacing Clin Electrophysiol 38:472–482. https://doi.org/10.1111/pace.12580CrossRefPubMed

36.

Lee HS, Park CW, Lee JS, Seo JT (2017) Hypogonadism makes dyslipidemia in Klinefelter's syndrome. J Korean Med Sci 32:1848–1851. https://doi.org/10.3346/jkms.2017.32.11.1848CrossRefPubMedPubMedCentral

37.

Sasagawa I, Nakada T, Kazama T, Terada T, Katayama T (1989) Testosterone replacement therapy and prostate/seminal vesicle volume in Klinefelter's syndrome. Arch Androl 22:245–249. https://doi.org/10.3109/01485018908986780CrossRefPubMed

38.

Choi HR, Lim SK, Lee MS (1995) Site-specific effect of testosterone on bone mineral density in male hypogonadism. J Korean Med Sci 10:431–435. https://doi.org/10.3346/jkms.1995.10.6.431CrossRefPubMedPubMedCentral

39.

Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A, Gundogan MA (1996) Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 81:3372–3378. https://doi.org/10.1210/jcem.81.9.8784099CrossRefPubMed

40.

Ozata M, Bulur M, Beyhan Z, Sengül A, Saglam M, Turan M, Corakci A, Ali Gundogan M (1997) Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism. Endocr J 44:719–724. https://doi.org/10.1507/endocrj.44.719CrossRefPubMed

41.

Ozata M, Ozisik G, Caglayan S, Yesilova Z, Bingöl N, Saglam M, Turan M, Beyhan Z (1998) Effects of gonadotropin and testosterone treatments on plasma leptin levels in male patients with idiopathic hypogonadotropic hypogonadism and Klinefelter's syndrome. Horm Metab Res 30:266–271. https://doi.org/10.1055/s-2007-978881CrossRefPubMed

42.

Shibasaki T, Sasagawa I, Suzuki Y, Yazawa H, Ichiyanagi O, Matsuki S, Miura M, Nakada T (2001) Effect of testosterone replacement therapy on serum PSA in patients with Klinefelter syndrome. Arch Androl 47:173–176. https://doi.org/10.1080/014850101753145861CrossRefPubMed

43.

Jiang-Feng M, Hong-Li X, Xue-Yan W, Min N, Shuang-Yu L, Hong-Ding X, Liang-Ming L (2012) Prevalence and risk factors of diabetes in patients with Klinefelter syndrome: a longitudinal observational study. Fertil Steril 98:1331–1335. https://doi.org/10.1016/j.fertnstert.2012.07.1122CrossRefPubMed

44.

Condorelli RA, Calogero AE, La Vignera S (2013) Different profile of endothelial cell apoptosis in patients with Klinefelter's syndrome. J Endocrinol Investig 36:84–91. https://doi.org/10.3275/8287CrossRef

45.

Jo DG, Lee HS, Joo YM, Seo JT (2013) Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Med J 54:1331–1335. https://doi.org/10.3349/ymj.2013.54.6.1331CrossRefPubMedPubMedCentral

46.

Chang S, Skakkebæk A, Trolle C, Bojesen A, Hertz JM, Cohen A, Hougaard DM, Wallentin M, Pedersen AD, Østergaard JR, Gravholt CH (2015) Anthropometry in Klinefelter syndrome—multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism. J Clin Endocrinol Metab 100:E508–E517. https://doi.org/10.1210/jc.2014-2834CrossRefPubMed

47.

Garolla A, Selice R, Menegazzo M, Valente U, Zattoni F, Iafrate M, Prayer-Galetti T, Gardiman MP, Ferlin A, Di Nisio A, Foresta C (2018) Novel insights on testicular volume and testosterone replacement therapy in Klinefelter patients undergoing testicular sperm extraction. A retrospective clinical study. Clin Endocrinol (Oxf) 88:711–718. https://doi.org/10.1111/cen.13572CrossRef

48.

Granato S, Barbaro G, Di Giorgio MR, Rossi FM, Marzano C, Impronta F, Spaziani M, Anzuini A, Lenzi A, Radicioni AF (2019) Epicardial fat: the role of testosterone and lipid metabolism in a cohort of patients with Klinefelter syndrome. Metabolism 95:21–26. https://doi.org/10.1016/j.metabol.2019.03.002CrossRefPubMed

49.

Van den Bergh JP, Hermus AR, Spruyt AI, Sweep CG, Corstens FH, Smals AG (2001) Bone mineral density and quantitative ultrasound parameters in patients with Klinefelter's syndrome after long-term testosterone substitution. Osteoporos Int 12:55–62. https://doi.org/10.1007/s001980170158CrossRefPubMed

50.

Di Minno MN, Esposito D, Di Minno A, Accardo G, Lupoli G, Cittadini A, Giugliano D, Pasquali D (2015) Increased platelet reactivity in Klinefelter men: something new to consider. Andrology 3:876–881. https://doi.org/10.1111/andr.12080CrossRefPubMed

51.

Higgins JPT, Green S (2008) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. https://www.cochrane-handbook.org. Accessed 6 Feb 2020

52.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101. https://doi.org/10.2307/2533446CrossRefPubMed

53.

Corona G, Rastrelli G, Reisman Y, Sforza A, Maggi M (2018) The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opin Drug Saf 17:277–292. https://doi.org/10.1080/14740338.2018.1424831CrossRefPubMed

54.

Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Resnick SM, Budoff M, Mohler ER 3rd, Wenger NK, Cohen HJ, Schrier S, Keaveny TM, Kopperdahl D, Lee D, Cifelli D, Ellenberg SS (2018) Lessons from the testosterone trials. Endocr Rev 39:369–386. https://doi.org/10.1210/er.2017-00234CrossRefPubMedPubMedCentral

55.

Mohr BA, Guay AT, O'Donnell AB, McKinlay JB (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 62:64–73. https://doi.org/10.1111/j.1365-2265.2004.02174.xCrossRef

56.

Corona G, Maseroli E, Rastrelli G, Francomano D, Aversa A, Hackett GI, Ferri S, Sforza A, Maggi M (2016) Is late-onset hypogonadotropic hypogonadism a specificage-dependent disease, or merely an epiphenomenon caused by accumulating disease-burden? Minerva Endocrinol 41(2):196–210PubMed

57.

Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group (2010) Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95:1810–1818. https://doi.org/10.1210/jc.2009-1796CrossRefPubMed

58.

Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M (2018) Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med 15:820–838. https://doi.org/10.1016/j.jsxm.2018.04.641CrossRefPubMed

59.

Corona G, Rastrelli G, Guaraldi F, Tortorici G, Reismann Y, Sforza A, Maggi M (2019) An update on heart disease risk associated with testosterone boosting medications. Expert Opin Drug Saf 18:321–332. https://doi.org/10.1016/j.jsxm.2018.04.641CrossRefPubMed

60.

Gagliano-Jucá T, Basaria S (2019) Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol 16:555–574. https://doi.org/10.1038/s41569-019-0211-4CrossRefPubMed

61.

Grossmann M, Matsumoto AM (2017) A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab 102:1067–1075. https://doi.org/10.1210/jc.2016-3580CrossRefPubMedPubMedCentral

62.

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103:1715–1744. https://doi.org/10.1210/jc.2018-00229CrossRefPubMed

63.

Yeap BB, Grossmann M, McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, Stuckey BG, Lording DW, Allan CA, Zajac JD, Burger HG (2016) Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Med J Aust 205:173–178. https://doi.org/10.5694/mja16.00393CrossRefPubMed

64.

FDA Drug Safety Communication: FDA cautions about using T products for low T due to aging requires labeling change to inform of possible increased risk of heart attack and stroke with use. Published 3 March 2015. https://www.fda.gov/Drugs/DrugSafety/ucm436259.htmforHumanMedicalProducts/ucm402054.htm. Accessed 6 Feb 2020

65.

Summary safety review-testosterone replacement product- cardiovascular risk. Published 15 July 2014. https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/testosterone-eng.php. Accessed 6 Feb 2020

66.

Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280–293. https://doi.org/10.1111/j.1365-2265.2005.02339.xCrossRef

67.

Tracz MJ, Sideras K, Boloña ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM (2006) Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91:2011–2016. https://doi.org/10.1210/jc.2006-0036CrossRefPubMed

68.

Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M (2018) Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med 15:1260–1271. https://doi.org/10.1016/j.jsxm.2018.06.012CrossRefPubMed

69.

Esposito D, Accardo G, Giallauria F, Bossone E, Vigorito C, Lenzi A, Pasquali D, Isidori AM, Cittadini A (2016) Klinefelter syndrome, cardiovascular system, and thromboembolic disease: Review of literature and clinical perspectives. Eur J Endocrinol. 175(1):R27–40. https://doi.org/10.1530/EJE-15-1025

Titel: Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis
verfasst von: A. Pizzocaro
W. Vena
R. Condorelli
A. Radicioni
G. Rastrelli
D. Pasquali
R. Selice
A. Ferlin
C. Foresta
E. A. Jannini
M. Maggi
A. Lenzi
R. Pivonello
A. M. Isidori
A. Garolla
S. Francavilla
G. Corona
the King, Klinefelter ItaliaN Group
Publikationsdatum: 01.12.2020
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 12/2020
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-020-01299-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Testosterone treatment in male patients with Klinefelter syndrome: a systematic review and meta-analysis